Sulfaproxyline is a sulfonamide derivative patented by J. R. Geigy A.-G. as an antibiotic, useful in the treatment of urinary tract infections. In preclinical models, sulfaproxyline is effective against staphylococci infection in guinea pigs. Bisulfon D, a drug product comprising the combination of sulfaproxyline and sulfamerazine has been used for the treatment of urinary tract infections in the puerperium.

Sulnidazole is a nitroimidazole derivative patented by Belgian pharmaceutical company Janssen Pharmaceutica N. V. as an antiprotozoal agent that effective against Trichomonas vaginalis.

Sulocarbilate (also known as W-1548-1) is a sulfanilamide derivative and carbonic anhydrase inhibitor with diuretic activity. In preclinical models, Sulocarbilate shows similar efficacy and superior safety profile compared to other agents of this type. Clinically, Sulocarbilate shows the maximum effect as a natriuretic agent in an oral daily dose of 2 g.

Sulosemide is a sulfamoylorthanilic acid derivative patented by German chemicals then life-sciences company Hoechst A.-G. as salidiuretic agent.

Sulukast (also known as LY170680 ) is an antagonist of the cysteinyl leukotrienes C4, D4, E4 patented by Lilly Industries Ltd. for the treatment of asthma. In vitro, Sulukast was a potent, selective, and competitive antagonist of LTD4, and LTE4. It produced a concentration-dependent rightward displacement of the concentration-response curves elicited by either LTD4 or LTE4 on both the guinea-pig ileal and tracheal preparation. Intravenous Sulukast reduced in a dose-dependent manner the fall in compliance in the anesthetized guinea-pig, and the rise in total pulmonary resistance. Sulukast was also effective in reducing the increase in total pulmonary resistance to intravenous antigen in sensitized animals pretreated with mepyramine, indomethacin, and propranolol. Inhaled Sulukast was particularly effective in preventing the increase in total pulmonary resistance produced by exposure to aerosolized LTD4.

TPI-287 is a microtubule stabilizer. TPI-287 readily crossed the normal BBB. While paclitaxel and TPI-287 showed similar cytotoxicity to breast cancer cells in vitro, and in a model of primary breast tumors, only TPI-287 was able to significantly reduce metastatic colonization of breast cancer in the brain. TPI-287 is a poor substrate for the P-gp efflux pump. Potential limitation to the clinical use of TPI-287 is the weight loss observed upon treatment. This loss recovered after cessation of treatment in the early treatment model, and may be ameliorated by hydration. TPI 287 was well tolerated by pediatric patients with refractory and relapsed neuroblastoma and medulloblastoma. The combination of TPI 287 and temozolomide is well tolerated in patients with metastatic melanoma, with the exception of neuropathy. TPI 287 is in phase II clinical trial for the treatment of breast cancer, glioblastoma and malignant melanoma.

Tenilapine is an atypical antipsychotic drug that acts as a potent inverse agonist at 5-HT(2C) receptor. In addition, tenilapine has relatively low affinities for the D4 receptor. Information about the current application of this drug is not available.

Terbequinil (previously known as SR 25776), a nootropic agent, is a partial inverse agonist of benzodiazepine receptor with psychostimulant activity. This drug participated in clinical trials for the treatment of cognition disorders and major depressive disorder. However, the development of terbequinil was discontinued during clinical trials in France.